Rocket Pharmaceuticals Q1 EPS $(0.66) Beats $(0.69) Estimate
Portfolio Pulse from Benzinga Newsdesk
Rocket Pharmaceuticals (NASDAQ:RCKT) reported Q1 earnings with losses of $(0.66) per share, surpassing the analyst consensus estimate of $(0.69) by 4.35%. This represents a 9.59% improvement over the previous year's losses of $(0.73) per share.
May 06, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rocket Pharmaceuticals reported a smaller loss than expected in Q1, with EPS of $(0.66) against estimates of $(0.69), showing improvement from last year.
Beating EPS estimates and showing year-over-year improvement is generally viewed positively by the market, likely leading to a short-term positive impact on RCKT's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100